SETD3

Across TCGA pan-cancer cohorts, SETD3 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated SETD3 data layer compared with 23 for mass-spec protein and 7 for mass-spec protein.

The strongest signal is observed in breast invasive carcinoma (BRCA), where higher SETD3 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated SETD3 expression acts as an unfavorable survival marker.

BRCA, COAD, and PRAD are the cancer types where SETD3 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BRCA	OS	Median	All	0.313	0.924	<.001	36	view →
COAD	OS	Median	All	0.125	0.799	.003	15	view →
PRAD	DFS	Median	All	0.617	0.886	.015	6	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

SETD3–BRCA (OS)

Open the BRCA breakdown →